Vaxcyte, Inc. (PCVX) stock analysis
In our weekly check, Vaxcyte, Inc. is graded F (A to F). Of 18 checks on debt, profit, cash flow and trend: 4 pass, warnings: 3, red flags: 11.
About Vaxcyte, Inc.
Vaxcyte, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as PCVX.
What our checks show for PCVX
Red flags
- The company has net debt but no positive operating earnings (EBITDA) to service it from (debt/equity 0.09).
- Weak EPS forecast
- Analysts expect the net margin to shrink by 1282 points from today's 0%.
- Weak EPS growth
- The company has no revenue yet.
- Free cash flow is negative and the company has no revenue yet: it lives on its cash and new funding.
- The price swings a lot: 52.5% annual volatility. Expect large ups and downs.
- The stock has fallen as much as 76% from a peak. Would you have held through that?
- The share count grew by 40.1% in 2 years: each shareholder owns a smaller slice.
- Return on capital (ROCE) is zero or negative: the business does not earn on the money put into it.
- Free cash flow is negative, so no cash is left over to cover pay in shares.
Warning signs
- Operating cash flow is negative while the company reports a profit: the profit does not arrive as cash.
- The stock is still below its previous peak.
- Beta 1.29: the stock usually moves more than the market, both up and down.
Strengths
- A large company: market value $10.03 billion.
- Actively traded: about 2.2 million shares a day.
Similar companies
MDGL · SYRE · TGTX · KYMR · PRAX · BMRN
Questions
What grade does Vaxcyte, Inc. (PCVX) have?
In our weekly check, Vaxcyte, Inc. is graded F (A to F). Of 18 checks on debt, profit, cash flow and trend: 4 pass, warnings: 3, red flags: 11. The grade is a risk check, not a buy or sell recommendation.
What are the main risks of PCVX stock?
This week's biggest flags for Vaxcyte, Inc.: High debt, Weak EPS forecast, Margins expected to shrink. In total 14 of 18 checks show a warning or a red flag.
What does Vaxcyte, Inc. do?
Vaxcyte, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as PCVX.
The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.
Updated 2026-11-14
Open the full analysis